Catalogs from TargetMol
Endocrinology & Metabolism
Endocrine disorders or metabolic abnormalities caused by factors such as genetics, unhealthy lifestyle habits, medication use, or autoimmune diseases directly increase the risk of conditions such as obesity, hypertension, atherosclerosis, diabetes, and fatty liver disease. Research on endocrinology and metabolism is a vital component of biomedical studies and a prerequisite for developing treatments for human diseases. TargetMol provides you with a variety of products related to endocrinology and metabolism, including active compounds, compound libraries and recombinant proteins. Released May 2025.
Cardiovascular Diseases
Cardiovascular diseases (CVD) encompass heart diseases and peripheral vascular diseases, including coronary heart disease, angina, cerebrovascular diseases, rheumatic heart disease, and other conditions. They are caused by various factors, such as high cholesterol, hypertension, obesity, smoking, and diabetes. As a one-stop drug screening expert, TargetMol offers a range of inhibitors & agonists, recombinant proteins, compound libraries, and drug-like compound libraries related for your drug screening and drug development projects. Released May 2025.
Natural Products
A natural product is a chemical compound produced by a living organism found in nature. In Biochemistry, they are mainly flavonoids, alkaloids, polysaccharides, volatile oils, quinones, terpenoids, lignans, coumarins, saponins, cardiac glycosides, phenolic acids, amino acids and enzymes. Naturally occurring compounds have been used medicinally for centuries and continue to be a rich source of novel therapeutics. TargetMol offers over 180,000 natural products and more than 30 natural product libraries, suitable for high-throughput screening and other research purposes. HNMR, HPLC, and GC are validated to ensure accurate product structures and high purity. Released May 2025.
Drug Repurposing
Drug repurposing, also known as the new use of old drugs, is a strategic approach to discover new applications for old or investigational drugs beyond their original approved applications. While the development of new drugs is a process with a high failure rate, high cost, and slow pace, repositioning old drugs for common and rare diseases is becoming increasingly attractive because of the advantages of low R&D costs and short development time. TargetMol provides various drug repurposing compound libraries including Bioactive Libraries, Drug Repurposing Compound Library, (FDA-)Approved Drug Library, Clinical Compound Library and more. Released May 2025.
Natural Product Library
Natural products are compounds produced by organisms in nature. Their highly diverse structures and functions have been selected and optimized during the long evolutionary process of nature. TargetMol's Natural Product Library for HTS has a collection of 3760 carefully selected natural product monomers from a wide range of sources including plants, animals and microbial species. These natural product monomers are structurally diversed and highly representative, making the Natural Product Library a powerful tool for drug development, pharmacological research, stem cell differentiation, fingerprint research, quality control research and other fields. Released August 2024.
Compound Library
A compound library is a collection of small molecule compounds assembled based on specific characteristics, usually used as a tool for high-throughput screening and drug discovery, assisting in the identification of lead compounds. The compound libraries from TargetMol come with a clear classification, detailed information and are continuously updated. Benefit from FDA-approved and repurposing libraries, disease- and target/pathway-focused libraries, bioactive libraries as well as natural product libraries. Released August 2024.
Inhibitors & Agonists of Signaling Pathways
Small molecule inhibitors and agonists can bind to targets (proteins/genes/RNA) and reduce their biological activity. They are used as tool compounds in biological and pharmacological research. Small molecule inhibitors and agonists have many advantages: high purity with clear chemical composition, more stable and low variation between batches, dose response is informative, dose can be easily manipulated, and more. TargetMol can provide a variety of small molecule inhibitors and agonists of hot signaling pathways for research and development. Released August 2024.
Targeted Antitumor Drugs: Monoclonal Antibodies
Targeted antitumor drugs are a class of therapies that use specific structural molecules on tumor tissues or cells as targets, and use certain antibodies and ligands that can specifically bind to these target molecules for direct or directed treatment purposes. Targeted drugs can be divided into two categories: small molecule drugs and monoclonal antibodies. In recent years, monoclonal antibody drugs have developed rapidly and gradually become the main direction of development in the field of biopharmaceuticals. Released August 2024.
TargetMol - Always ready to target Cancer
Malignant tumors (cancers) are one of the major medical problems posing a serious threat to human health, and for many years, human beings have been continuously conducting research on anti-tumor drugs. TargetMol is always at the forefront of cancer-focused research. The company provides comprehensive resources, including anti-tumor related small molecules, compound libraries, recombinant proteins, and antibodies to support antitumor drug discovery. They also provide computer-aided drug discovery services tailored for your research on cancer-related drug screening. Released August 2024.
Stem Cells & Organoids
Stem cells are a type of primitive cell that can self-renew and differentiate into various tissue cells. Organoids are generated from human pluripotent stem cells or adult stem cells and represent one of the key advancements in stem cell research. They are 3D cell clusters cultured in vitro, capable of self-renewal and self-organization, and possess the functions of the tissue or organ they originate from. The advent of human 3D organoids allows us to observe stem cells' morphology, maintenance, and differentiation, which is similar to the original tissues. Released August 2024.
Neurodegenerative Diseases
Neurodegenerative diseases are heterogeneous neurological disorders, including Alzheimer's Disease, Parkinson's Disease, Huntington's Disease or Amyotrophic Lateral Sclerosis (ALS). These diseases cause the gradual loss of neurons in the central or in the peripheral nervous system, which ultimately leads to impairments in memory, cognition, behaviour, sensation and/or motor functions. As a leading supplier in the field of drug discovery, TargetMol offers various products related to the research on such neurodegenerative diseases. Released August 2024.
Recombinant Proteins
TargetMol currently offers over 13,000 recombinant protein products with low endotoxin levels (tested by LAL assay), covering several categories including cytokines, growth factors, receptor proteins, enzymes and viral proteins. Multiple expression systems can be selected, including prokaryotic systems, mammalian cells, yeast and insects etc. TargetMol also provides a variety of species options and tag choices. Most of the products are supplied carrier-free and in lyophilized powder to ensure protein stability. Released August 2024.
TargetMol - Targets Molecules in your Research
TargetMol Chemicals Inc. specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a portfolio of more than 50,000 products, TargetMol has evolved into one of the biggest global research suppliers. Discover over 800 compound libraries, more than 20,000 inhibitors & agonists, 16,000+ natural products and a collection of over 13,000 recombinant proteins. Released August 2024.